|
|
|
|
Whose Afraid of Authorized Generics
No brand manufacturers plan to market generic versions of their own product, at least not until the patent expires. And why would they? As long as the branded version enjoys patent protection, marketing a cut-rate product would eat away profit margin during the years when a drug makes the most money.
|
| |
More>>
|
|
|
|
|
|
Under the Influence
Sales reps should be able to access, in a central location, company-enerated influences that have affected a given physician. This type of closed-
loop marketing creates a more customer-centric approach that provides etter influencer-level insight by connecting each resource, providing direction and metrics, and continually re-evaluating key influences and ROI.
|
| |
More>>
|
|
|
|
|
|
Cervical Cancer: Endangered Species
It's busy at merck these days— and not just in the Vioxx
legal department. Instead, the entire office buzzes with activity:
Executives work late hours, finalizing the regulatory submission;
conference calls echo throughout the Whitehouse Station compound,
dialed in to local affiliates around the world. In other offices,
scientists write up scientific papers, while communications execs
buzz in on intercoms, patching the flood of media calls to top
scientists.
|
| |
More>>
|
|
|
|
|
|
Major drugs lose patent protection in 2006
This year is the first in a string of what could be very good years for the generic drug industry. About $12 billion worth of brand-name drugs lose patent protection this year, according to pharmacy benefit manager Express Scripts. Another $11 billion in branded products go off patent in 2007, $10 billion in 2008, and even more in 2009 and 2010.
|
| |
More>>
|
|
|
